ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)

This study has been completed.
Study NCT00000487.   Last updated on June 23, 2005.   Information provided by National Heart, Lung, and Blood Institute (NHLBI)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)
Official Title 
Brief Summary

To determine for a group of men at high risk of death from coronary heart disease whether a special intervention program to lower serum cholesterol, reduce blood pressure, and eliminate cigarette smoking would result in a significant reduction in mortality from coronary heart disease.

Detailed Description

BACKGROUND:

Research findings from prospective epidemiological studies in a number of populations in the United States over the past 40 years have convincingly established that elevated blood cholesterol, elevated blood pressure, and cigarette smoking are risk factors associated with accelerated development of myocardial infarction, sudden death, and death from coronary heart disease. These are not the only risk factors associated with premature development of CHD, but these factors are modifiable and provide a strong expectation that a reduction of these factors should have a beneficial result of reducing the rate of development of premature heart attacks.

A multifactor approach to risk factor reduction closely resembles the type of intervention that would be carried out by a physician in his treatment of a patient. The general concept for such a trial was endorsed by the Arteriosclerosis Task Force in its 1970 report to the Institute.

Volunteers were selected for the trial through a series of three screening visits, which began in November 1973 and were completed by February 28, 1976. From among 361,662 men seen at first screening, 12,866 were found to be eligible and were randomized into the trial. Half of the participants were assigned to the special intervention group and half to the usual care group. The special intervention group was advised to follow an eating pattern designed to result in a nutrient intake of 30 percent to 35 percent of calories from fat, with 10 (later 8) percent from saturated and 10 percent from polyunsaturated fat; approximately 300 (later 250) mg of cholesterol; and modification of carbohydrates as needed for individual requirements. This group was also encouraged to cease cigarette smoking by a combination of techniques, including counseling and audio-visual aids. Hypertension management was based on a stepped-care program of weight reduction and drugs similar to that used in the Hypertension Detection and Follow-up Program. Those in the usual care group were referred to their personal physician or other source of care for such management of their risk factors as considered appropriate by these providers. The primary endpoint was death due to coronary heart disease. Men in both the special intervention and usual care groups returned for assessment of changes in risk factor levels annually. A medical history was taken and a physical examination performed. An electrocardiogram was also obtained for centralized reading to identify non-fatal myocardial infarction as an additional endpoint.

Participating in the study were 22 clinical centers across the United States, a coordinating center, central laboratory, two ECG reading centers, and lipid standardization laboratory, as well as a drug distribution center. The trial has concluded, with the main mortality results published in September l982. Active follow-up was terminated on schedule on February 28, l982, with final determination of vital status as of that date accomplished for 99.6 percent of the study population.

DESIGN NARRATIVE:

A randomized, non-blind design with two groups and fixed sample size. The experimental group underwent a modified-fat diet, antihypertensive therapy, and education related to lifestyle and smoking. Those in the control group were referred to their own physicians for treatment.

Post-trial mortality surveillance of the 12,300 participants still living at the end of active intervention in February 1982 continued through June 1998 under grant support (R01HL43232). Use of the National Death Index for mortality surveillance of the 361,662 men screened for the MRFIT continued thorough July 1998 under grant support (R01HL28715). Recent analyses focus on the relationship of dietary factors, such as sodium, during the trial with post-trial mortality. Papers are in progress on further predictors of diabetes mellitus; indicators of cardiovascular disease morbidity and risk of death; and prognostic importance of changes in indices of left ventricular hypertrophy and ischemia.

Study Phase Phase III
Study Type  Interventional
Study Design  Prevention, Randomized
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Intervention  Drug: antihypertensive agents
Behavioral: smoking cessation
Behavioral: diet, fat-restricted
Drug: diuretics
MEDLINE PMIDs 946311,   946878,   361920,   218069,   447782,   484765,   7391467,   6998287,   7365351,   7400494,   6893713,   7391468,   7391469,   7217577,   7027234,   7027236,   7027237,   7027238,   7027239,   7027240,   7027241,   7027242,   7050440,   6761682,   7122434,   6625030,   6499702,   6475745,   6367451,   6475754,   3880997,   3893343,   2857061,   4046122,   3885701,   3903734,   4025299,   4061439,   4087288,   3953436,   3711503,   3532744,   3773199,   3946459,   3704083,   2416486,   2877128,   3519737,   3519736,   3706160,   3519738,   3749007,   2873741,   3802835,   3802842,   3802845,   3802846,   3802847,   3802848,   3802837,   3802838,   3802839,   3802840,   3802843,   3669210,   3661526,   3661391,   2442992,   3499090,   3440389,   3815790,   3612777,   3806876,   3277736,   2521269,   2619783,   2731108,   2782764,   2179590,   2225366,   2372006,   2368857,   2213869,   2057467,   1755441,   1955253,   2279793,   1665114,   1758837,   1758838,   1758839,   1758840,   1758841,   1758844,   1758843,   1580443,   1433739,   1627030,   1728930,   8189111,   8167825,   8269790,   8465834,   8432214,   8363210,   8296783,   8205270,   8921782,   8797513,   8610702,   7586343,   7738492,   863996,   360923,   1758842,   2053338,   8626955,   8790030,   8988936,   8988937,   8988938,   8988939,   8988940,   8988941,   8988942,   8988943,   8988944,   8988945,   8988946,   8988947,   8988948,   8988949,   8898781,   8629606,   9109467,   9230148,   9272851,   9099400,   9403420,   9734939,   9457009,   9758118,   11339440,   11165468,   9801015,   15738450
Links
Recruitment Information Fields
Recruitment Status  Completed
Enrollment 
Start Date  June 1972
Completion Date July 1998
Eligibility Criteria 

Men, ages 35-57. One or more of three risk factors--hypertension, hypercholesterolemia, and cigarette smoking.

Free from coronary heart disease.

Gender Male
Ages 35 Years to 57 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries 
Administrative Information Fields
NCT ID  NCT00000487
Organization ID 6
Secondary IDs ††
Study Sponsor  National Heart, Lung, and Blood Institute (NHLBI)
Collaborators ††
Investigators 
Investigator:     Marcus Kjelsberg     University of Minnesota    
Information Provided By National Heart, Lung, and Blood Institute (NHLBI)
Verification Date March 2005
First Received Date  October 27, 1999
Last Updated Date June 23, 2005

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers